H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on BridgeBio (BBIO) to $53 from $49 and keeps a Buy rating on the ...

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In this article, we are going to take a look at where BridgeBio Pharma (NASDAQ:BBIO) stands against the other stocks. Stock gains always get people talking, and 2025 is no exception. Markets have ...

In trading on Wednesday, shares of BridgeBio Pharma Inc (Symbol: BBIO) crossed below their 200 day moving average of $28.50, changing hands as low as $28.32 per share. BridgeBio Pharma Inc shares ...

Pharma presented results showing statistically significant improvements in clinical outcomes as compared to placebo for time ...

NASDAQ:BBIO opened at $34.90 on Friday. The firm has a market cap of $6.64 billion, a price-to-earnings ratio of -12.25 and a beta of 1.07. The company’s 50-day moving average is $32.68 and its ...

PALO ALTO, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers.